357 related articles for article (PubMed ID: 30926062)
1. The prognosis of head and neck squamous cell carcinoma related to immunosuppressive tumor microenvironment regulated by IL-6 signaling.
Tsai MS; Chen WC; Lu CH; Chen MF
Oral Oncol; 2019 Apr; 91():47-55. PubMed ID: 30926062
[TBL] [Abstract][Full Text] [Related]
2. The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation.
Yu D; Liu X; Han G; Liu Y; Zhao X; Wang D; Bian X; Gu T; Wen L
Cell Commun Signal; 2019 Dec; 17(1):173. PubMed ID: 31881947
[TBL] [Abstract][Full Text] [Related]
3. Expression level of PD-L1 is involved in ALDH1A1-mediated poor prognosis in patients with head and neck squamous cell carcinoma.
Zhou AL; Wang X; Yu W; Yang L; Wei F; Sun Q; Wang Y; Kou F; Dong R; Ren X; Zhang X
Pathol Res Pract; 2020 Sep; 216(9):153093. PubMed ID: 32825960
[TBL] [Abstract][Full Text] [Related]
4. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
[TBL] [Abstract][Full Text] [Related]
5. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
[TBL] [Abstract][Full Text] [Related]
6. TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells.
Mao L; Xiao Y; Yang QC; Yang SC; Yang LL; Sun ZJ
Oral Oncol; 2021 Oct; 121():105472. PubMed ID: 34333450
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with Head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation.
Rühle A; Grosu AL; Wiedenmann N; Mix M; Stoian R; Niedermann G; Baltas D; Werner M; Weber WA; Kayser G; Nicolay NH
Theranostics; 2020; 10(20):9395-9406. PubMed ID: 32802199
[TBL] [Abstract][Full Text] [Related]
8. HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings.
Boschert V; Teusch J; Aljasem A; Schmucker P; Klenk N; Straub A; Bittrich M; Seher A; Linz C; Müller-Richter UDA; Hartmann S
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233528
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas.
Succaria F; Kvistborg P; Stein JE; Engle EL; McMiller TL; Rooper LM; Thompson E; Berger AE; van den Brekel M; Zuur CL; Haanen J; Topalian SL; Taube JM
Cancer Immunol Immunother; 2021 May; 70(5):1227-1237. PubMed ID: 33125511
[TBL] [Abstract][Full Text] [Related]
10. Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage.
Hira-Miyazawa M; Nakamura H; Hirai M; Kobayashi Y; Kitahara H; Bou-Gharios G; Kawashiri S
Int J Oncol; 2018 Feb; 52(2):379-388. PubMed ID: 29345283
[TBL] [Abstract][Full Text] [Related]
11. Predictive Value of the Pretreatment Neutrophil-to-Lymphocyte Ratio in Head and Neck Squamous Cell Carcinoma.
Chen MF; Tsai MS; Chen WC; Chen PT
J Clin Med; 2018 Sep; 7(10):. PubMed ID: 30241364
[TBL] [Abstract][Full Text] [Related]
12. The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.
Qiao XW; Jiang J; Pang X; Huang MC; Tang YJ; Liang XH; Tang YL
Front Immunol; 2020; 11():1721. PubMed ID: 33072064
[TBL] [Abstract][Full Text] [Related]
13. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma.
Wang J; Sun H; Zeng Q; Guo XJ; Wang H; Liu HH; Dong ZY
Sci Rep; 2019 Sep; 9(1):13404. PubMed ID: 31527697
[TBL] [Abstract][Full Text] [Related]
14. SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Pai SI; Cohen EEW; Lin D; Fountzilas G; Kim ES; Mehlhorn H; Baste N; Clayburgh D; Lipworth L; Resteghini C; Shara N; Fujii T; Zhang J; Stokes M; Wang H; Twumasi-Ankrah P; Wildsmith S; Khaliq A; Melillo G; Shire N
J Transl Med; 2019 Dec; 17(1):429. PubMed ID: 31878938
[TBL] [Abstract][Full Text] [Related]
15. Expression of PD-1/PD-L1 in head and neck squamous cell carcinoma and its clinical significance.
Chen SW; Li SH; Shi DB; Jiang WM; Song M; Yang AK; Li YD; Bei JX; Chen WK; Zhang Q
Int J Biol Markers; 2019 Dec; 34(4):398-405. PubMed ID: 31674884
[TBL] [Abstract][Full Text] [Related]
16. CD244 represents a new therapeutic target in head and neck squamous cell carcinoma.
Agresta L; Lehn M; Lampe K; Cantrell R; Hennies C; Szabo S; Wise-Draper T; Conforti L; Hoebe K; Janssen EM
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217758
[TBL] [Abstract][Full Text] [Related]
17. Clinical Significance of PD-L1
Theodoraki MN; Yerneni SS; Hoffmann TK; Gooding WE; Whiteside TL
Clin Cancer Res; 2018 Feb; 24(4):896-905. PubMed ID: 29233903
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma.
Evrard D; Hourseau M; Couvelard A; Paradis V; Gauthier H; Raymond E; Halimi C; Barry B; Faivre S
Oncoimmunology; 2020 Nov; 9(1):1844403. PubMed ID: 33299655
[TBL] [Abstract][Full Text] [Related]
19. Genome-wide open reading frame profiling identifies fibroblast growth factor signaling as a driver of PD-L1 expression in head and neck squamous cell carcinoma.
Mann JE; Smith JD; Kulkarni A; Foltin SK; Scheftz EB; Murray IR; Gensterblum-Miller E; Brummel CV; Bhangale A; Hoesli RC; Brenner JC
Oral Oncol; 2023 Nov; 146():106562. PubMed ID: 37666053
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma.
Strati A; Koutsodontis G; Papaxoinis G; Angelidis I; Zavridou M; Economopoulou P; Kotsantis I; Avgeris M; Mazel M; Perisanidis C; Sasaki C; Alix-Panabières C; Lianidou E; Psyrri A
Ann Oncol; 2017 Aug; 28(8):1923-1933. PubMed ID: 28838214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
